Drug Profile


Alternative Names: TAK-438; TAKECAB; VONOPION® pack; Vonoprazan fumarate; VONOSAP® pack 400; VONOSAP® pack 800

Latest Information Update: 27 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Class Amines; Antiulcers; Pyridines; Pyrroles; Small molecules; Sulfonamides
  • Mechanism of Action Potassium-competitive acid blockers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Duodenal ulcer; Erosive oesophagitis; Gastric ulcer; Gastro-oesophageal reflux; Helicobacter infections; Peptic ulcer; Reflux oesophagitis

Most Recent Events

  • 17 Aug 2017 Takeda completes a phase I pharmacokinetics trial in Healthy volunteers in China (NCT03085836)
  • 27 Jul 2017 Takeda completes a phase III trial in Erosive esophagitis in China, South Korea, Malaysia and Taiwan (NCT02388724)
  • 11 May 2017 Takeda completes a phase I trial in Helicobacter infections (Combination therapy) in South Korea (PO) (NCT02892409)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top